The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Batch water processes for producing high functionality polyether polyols from polyhydroxyl compounds that are solid at ambient conditions, such as is the case with sucrose, are disclosed. The disclosed processes avoid use of an intermediate dewatering step.

Batch water processes for producing high functionality polyether polyols from polyhydroxyl compounds that are solid at ambient conditions, such as is the case with sucrose, are disclosed. The disclosed processes avoid use of an intermediate dewatering step.

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

Batch water processes for producing high functionality polyether polyols from polyhydroxyl compounds that are solid at ambient conditions, such as is the case with sucrose, are disclosed. The disclosed processes avoid use of an intermediate dewatering step.

Batch water processes for producing high functionality polyether polyols from polyhydroxyl compounds that are solid at ambient conditions, such as is the case with sucrose, are disclosed. The disclosed processes avoid use of an intermediate dewatering step.

The invention comprises a new process for the preparation of GalNAc derivatives of the formula I ##STR00001## wherein n is an integer between 0 and 10 and its salts, corresponding enantiomers and/or optical isomers thereof. The GalNAc acid derivative of formula I can be used for the preparation of therapeutically valuable GalNAc oligonucleotide conjugates.